Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Multi-center Randomized Clinical Trial to Determine the Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein (VG712) in Subjects With Mycosis Fungoides (CurbMF Trial)

NCT07529405 is registered in ClinicalTrials.gov with Virogen Biotechnology Inc. as lead sponsor.

NCT NCT07529405
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07529405 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Multi-center Randomized Clinical Trial to Determine the Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein (VG712) in Subjects With Mycosis Fungoides (CurbMF Trial)
Lead sponsor
Virogen Biotechnology Inc.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
July 30, 2026
Completion date
December 30, 2032
Enrollment
386 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mycosis fungoides